A Prospective, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

Schizophrenia is a long-lasting and serious mental health disorder that affects about 1% of people worldwide. It can cause symptoms such as hallucinations and delusions (called positive symptoms), confused or disorganized thinking, reduced motivation and emotional expression (negative symptoms), difficulties with memory and concentration (cognitive symptoms), and movement problems like restlessness or slowed activity. Current treatments, called antipsychotics, mainly work by blocking dopamine in the brain. These medicines are helpful for hallucinations and delusions, but they do little to improve negative or cognitive symptoms.
A new medicine, Xanomeline/Trospium (XT), works differently. It targets a brain system called the muscarinic acetylcholine receptors while limiting side effects elsewhere in the body. Clinical trials have shown that XT reduces psychotic symptoms effectively and is generally well tolerated. The FDA approved XT in 2024 for adults with schizophrenia. Importantly, early results also suggest that XT may help improve thinking and memory (cognition domains), though this has not yet been studied in depth.
Most schizophrenia drug studies pay little attention to long-term changes in cognition, often using only short screening tests. This study will be the first to take a deep look at cognitive function over a full year of XT treatment. It will also examine how changes in thinking skills connect with other aspects of life, such as symptom control, daily functioning, and quality of life. By making cognition a central outcome, the study responds to an urgent need in schizophrenia research: moving beyond just controlling hallucinations and delusions toward improving real-world recovery. The results could help shape future treatment strategies and support the idea that cognition should be a core treatment target in schizophrenia.

Start Date01 Jan 2027

Sponsor / Collaborator

Universitair Medisch Centrum Groningen

[+1]

NCT07228338

/ Not yet recruitingEarly Phase 1IIT

Muscarinic Agonist Modulation of Memory Processing Oscillatory Activity

The goal of this study is to learn about the effects of Cobenfy KarXT (xanomeline and trospium chloride) on episodic memory processing, including specific effects on areas of the brain involved in memory and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.
The main questions it aims to answer are 1) whether Cobenfy KarXT changes memory activity based on its agonist effect on muscarinic receptors and acetylcholine, and 2) what the nature of these brain activity changes are. This work builds on previous experiments evaluating cholinergic antagonists.
Participants will complete two treatment arms. One of these will be with the drug, and the other will be control session. Participants will not be blinded to the study condition. Patients will complete a verbal serial recall and/or associative recognition task each of the two days. An anesthesiologist or patient nurse will administer either the drug or the placebo at a critical point which addresses both of the research questions.
Researchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and whether there is an additional behavioral effect on memory.

Start Date01 Dec 2026

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

NCT07285798

/ Not yet recruitingPhase 3

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of KarXT + KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder

The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.

Start Date02 Oct 2026

Sponsor / Collaborator

Bristol Myers Squibb Co.

100 Clinical Results associated with Xanomeline Tartrate/Trospium Chloride

100 Translational Medicine associated with Xanomeline Tartrate/Trospium Chloride

100 Patents (Medical) associated with Xanomeline Tartrate/Trospium Chloride

Literatures (Medical) associated with Xanomeline Tartrate/Trospium Chloride

01 Oct 2026·EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Effects of xanomeline–trospium on the gut–lung microbiota axis and susceptibility to LPS-induced acute lung injury in male and female mice

Article

Author: Murayama, Rumi ; Eguchi, Akifumi ; Yue, Yong ; Cai, Yi ; Yang, Jian-Jun ; Hashimoto, Kenji ; Ding, Xin

Xanomeline-trospium is a first-in-class muscarinic receptor-based antipsychotic that improves schizophrenia symptoms without dopamine D₂ receptor antagonism. Although gastrointestinal (GI) adverse effects have been reported, its broader effects on host microbiota and susceptibility to respiratory injury remain unclear. We investigated the effects of xanomeline and xanomeline-trospium on gut and lung microbiota, host metabolism, and outcomes in lipopolysaccharide (LPS)-induced acute lung injury (ALI) in male and female mice. Adult mice received vehicle, xanomeline, or xanomeline-trospium for 15 days. Body weight was monitored longitudinally, fecal output was measured, gut and lung microbiota were profiled using 16S rRNA sequencing, and untargeted serum metabolomics was performed using UPLC-QTOF/MS. ALI was induced by intratracheal LPS administration, and survival was assessed for seven days. Xanomeline induced weight loss in female mice and constipation in both sexes, and these effects were attenuated by trospium co-administration. Xanomeline-trospium was associated with sex- and region-associated alterations in gut microbiota, with greater remodeling in the cecum and colon, and also altered lung microbiota composition in both sexes. Integrated multi-omics analyses revealed sex-associated links among specific bacterial taxa, circulating metabolites, and host phenotypes. In the ALI model, xanomeline-trospium significantly increased LPS-induced mortality in female mice but not in male mice; however, formal interaction analysis did not support a significant sex-dependent treatment effect. These findings suggest that xanomeline-trospium alters gut-lung microbiota and host metabolic networks and may influence respiratory vulnerability.

01 Oct 2026·PSYCHIATRY RESEARCH

Post-marketing safety surveillance of the novel muscarinic antipsychotic Xanomeline-Trospium for schizophrenia: A comparative disproportionality analysis against olanzapine based on FAERS data

Article

Author: Liu, Yuxia ; Zeng, Yining ; Wang, Ruixia ; Wu, Hao ; Duan, Junguo ; Wang, Xueting ; Tan, Xiyue

OBJECTIVE:

To characterize the real-world post-marketing safety reporting profile and adverse event (AE) signals of Xanomeline-Trospium, a novel dual M1/M4 muscarinic antipsychotic for schizophrenia.

METHODS:

FAERS data from 2024Q4 to 2025Q4 were retrospectively analyzed. Reports listing Xanomeline-Trospium as the primary suspected drug were extracted. Signals were detected using four algorithms: ROR, PRR, BCPNN, and MGPS. Additional analyses included Weibull time-to-onset modeling, exploratory comparison with olanzapine, sex- and age-stratified subgroup analyses, and sensitivity analysis excluding concomitant medications.

RESULTS:

A total of 1410 valid reports were identified. After excluding underlying disease-related confounders, 42 clinically meaningful Preferred Terms showed positive signals. The reporting profile was dominated by gastrointestinal events, including nausea and projectile vomiting; renal and urinary events, especially urinary retention; and acute psychiatric activation, including intrusive thoughts and anger. Compared with olanzapine, Xanomeline-Trospium showed lower reporting odds for metabolic and extrapyramidal events but higher reporting odds for autonomic, gastrointestinal, and acute neurobehavioral signals. Sex subgroup analysis suggested potential divergent autonomic reporting patterns, with females showing more cholinergic signals and males showing more anticholinergic signals. Weibull analysis indicated an "early failure" pattern, with 86.8% of AEs occurring within 30 days of treatment initiation and a median onset of 6.4 days.

CONCLUSION:

Xanomeline-Trospium showed a distinct FAERS reporting profile characterized by gastrointestinal, urological, and acute psychiatric signals. These findings are hypothesis-generating associations rather than causal risks and support intensive monitoring during treatment initiation.

01 Sep 2026·CTS-Clinical and Translational Science

Xanomeline and Trospium Chloride: Mechanism of Action, Clinical, and Translational Science

Review

Author: Avila, Samantha ; Chen, Ingrid L.

ABSTRACT:

Xanomeline‐trospium chloride (Cobenfy, formerly KarXT) is a first‐in‐class, oral central M1/M4 muscarinic receptor agonist approved for the treatment of schizophrenia in adults. Cobenfy represents a paradigm shift by avoiding direct dopamine D2 receptor blockade and thus significantly reduces the burden of metabolic, extrapyramidal, and sedative side effects observed in standard first and second‐generation antipsychotics. Trospium chloride is a peripheral muscarinic antagonist with negligible blood–brain barrier penetration. Cobenfy is co‐formulated with trospium to minimize peripheral cholinergic effects caused by xanomeline. Under fasting conditions, xanomeline and trospium reach peak plasma concentrations ( Tmax ) in 2 and 1 h, and maximum concentrations ( Cmax ) of 1955 and 5787 pg/mL, respectively. While food intake does not change xanomeline pharmacokinetics, it reduces trospium Cmax by around 70%. Xanomeline has a high volume of distribution (10,800 L) and is metabolized by several cytochrome P450 (CYP) enzymes. Trospium is a P‐glycoprotein (P‐gp) substrate and is 85% eliminated in feces. In phase III clinical trials (EMERGENT‐2, EMERGENT‐3), Cobenfy significantly reduced PANSS total scores (least squares mean difference −9.6 and −8.4, respectively; p < 0.0001) compared to placebo. Treatment‐emergent adverse events were primarily mild to moderate in severity and were mainly transient nausea (19%), constipation (17%), dyspepsia (15%), and vomiting (14%). Discontinuation rates due to adverse events were low (6.2% vs. 5.2% for placebo), and Cobenfy was not associated with weight gain, extrapyramidal symptoms, or cardiometabolic risks seen in conventional antipsychotics.

371

News (Medical) associated with Xanomeline Tartrate/Trospium Chloride

29 Oct 2026

·www.fiercepharma.com

Bristol Myers' Cobenfy performance called into question amid overall Q3 revenue beat

Bristol Myers Squibb executives faced sharp questions from an analyst on Thursday regarding the slow commercial launch pace of its highly touted Cobenfy. The schizophrenia medicine’s performance was relatively underwhelming for the second quarter in a row. Despite a 30% sales bump compared to the same time last year, the $57 million in sales for the third quarter missed analyst estimates by $11 million. It doesn’t help that the drug came on the market with incredible hype. BMS acquired the therapy in 2024 for $14 billion and gained FDA approval the same year, sending expectations soaring over the first schizophrenia treatment with a novel mechanism of action in three decades. Some analysts projected $300 million in sales during its first year. In reality, the drug made a more subdued debut with $155 million in sales in 2025. Since its launch, analysts have cut the drug’s revenue predictions through 2030 by roughly 40%. On Thursday's earnings call, BMS’ chief commercialization officer, Adam Lenkowsky, noted that total prescription volume for Cobenfy increased by 3% to 4% for the quarter. But prescribing behaviors and side effects, alongside inventory issues specific to the third quarter, is weighing on the drug’s performance, he said. “We need to accelerate new patient starts. We need to improve repeat prescribing. I think one of the bigger challenges that we’ve seen is we’ve been educating physicians on the importance of rapidly titrating Cobenfy to the effective dose of 125 mg,” Lenkowsky said on the earnings call. According to Lenkowsky, far too many patients remain on the suboptimal 50 and 100-mg doses of Cobenfy due to the nausea and vomiting side effects during the initiation period. The better course of action, BMS said, is to titrate patients up to the full 125 mg and give antiemetics to manage the gastrointestinal issues. “When patients are on the effective dose and the GI toxicity is managed appropriately, we have truly seen remarkable results for this product,” Lenkowsky said. Cobenfy’s slow burn in schizophrenia has created apprehension around BMS’ closely watched phase 3 readouts in Alzheimer’s disease psychosis slated for next year. At 7 million patients in the U.S., Alzheimer’s represents a much bigger market. And about 30% to 50% of those patients experience psychosis, for which Cobenfy could be the first FDA-approved treatment if the clinical trials go as hoped. But BMS has already had to push back the readouts on two occasions: In December 2025, it delayed Adept-2 readouts because of site irregularities, and this summer, it delayed readouts of the Adept trials, citing slower-than-expected enrollment. The long-awaited results are set to come out just around the new year, and BMS needs positive results from two out of the three trials to approach the FDA. But even if the trials are a success, there’s skepticism about Cobenfy’s commercial potential and tolerability in the older Alzheimer’s population. To its advantage, Cobenfy is not associated with the boxed warnings that come with many of the existing antipsychotics, like sedation, cognitive impairment and movement disorders. “But that said, we will take the learnings from schizophrenia, and we’re going to need to set up expectations with patients and physicians, build confidence around managing the nausea and vomiting with Cobenfy,” he said. Beyond Cobenfy, BMS produced a strong quarter with a 7% increase in total revenue compared to the same time in 2025. William Blair analysts said the performance was largely driven by better-than-expected performance from the legacy portfolio, especially BMS’ blood cancer drug, Revlimid, which generated $303 million in Q3, well above analysts' estimates of $236 million. The company’s aging blood thinner, Eliquis, also saw a 25% jump in sales. BMS raised its revenue guidance for the year to $49.75 billion to $50.25 billion and assured that key readouts for milvexian—widely seen as BMS’ successor to Eliquis—and Cobenfy are still on track.

Phase 3Drug Approval

20 Oct 2026

·www.biospace.com

Slate Medicines Strengthens Board of Directors with Appointment of Stephen K. Brannan, MD, and John D. Young

RALEIGH, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Slate Medicines, Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and potentially improve outcomes for people with migraine and other headache disorders, today announced the appointment of Stephen K. Brannan, MD, and John D. Young to the company’s Board of Directors. Dr. Brannan brings more than 25 years of clinical development experience in CNS disorders and most recently served as the Chief Medical Officer of Karuna Therapeutics. Mr. Young brings more than 35 years of biopharmaceutical industry experience, including serving as a member of the Executive Leadership Team at Pfizer, most recently as Group President and Chief Business Officer. “We are pleased to welcome Stephen and John to the Slate Medicines Board, both of whom have complementary experience that is well matched to our priorities,” said Gregory Oakes, MBA, Chief Executive Officer of Slate Medicines. “Stephen has helped bring multiple CNS treatments from the clinic to approval, while John has shaped corporate strategy, partnerships and portfolio decisions at a leading global pharmaceutical company. Their guidance will be invaluable as we advance SLTE-1009 as well as our portfolio and work to bring much-needed new treatment options to migraine patients who remain underserved by current therapies.” Dr. Brannan served as Chief Medical Officer of Karuna Therapeutics from 2017 until 2024, overseeing clinical development of KarXT (xanomeline and trospium) through Phase 3 trials in schizophrenia, the program that led to the approval of Cobenfy ® (xanomeline and trospium chloride). Earlier in his career, he held clinical and medical leadership roles at Forum Pharmaceuticals, Takeda (including Therapeutic Area Head for CNS), Novartis, Cyberonics (now LivaNova) and Eli Lilly. Board-certified in psychiatry, Dr. Brannan received his AB from Harvard University and his MD from The University of Texas Southwestern Medical School. “Migraine remains a disease where many people are still looking for better options,” said Dr. Brannan. “SLTE-1009 is a potentially differentiated migraine preventative, and I look forward to working with the Slate team to apply the best practices needed for the successful development of CNS programs to realize the full potential of this innovative treatment option.” Mr. Young retired from Pfizer in 2022 after a 35-year career, most recently as Group President and Chief Business Officer. A member of Pfizer’s Executive Leadership Team, Mr. Young has deep experience in corporate strategy, business development, portfolio management, and commercialization. Mr. Young currently serves on the boards of Novartis AG and Johnson Controls International. He holds a BSc in Biological Sciences from the University of Glasgow and an MBA from Strathclyde Graduate Business School. “Slate has developed a compelling portfolio of assets that has the potential to impact the lives of migraine patients globally,” said Mr. Young. “I look forward to working with the Slate board of directors and broader team as they advance their programs.” About Slate Medicines, Inc. Slate Medicines is a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and potentially improve outcomes for people with migraine and other headache disorders. Slate is advancing a portfolio of potentially best-in-class therapeutics, led by SLTE-1009, a clinical-stage anti-PACAP/VIP monoclonal antibody designed to enable subcutaneous, infrequent dosing. For more information, please visit the Slate Medicines website. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of SLTE-1009 and Slate’s other product candidates to expand treatment options for migraine and other headache disorders; the potential for Slate’s portfolio of product candidates, including SLTE-1009, to be best-in-class or differentiated; and Slate’s research, development and regulatory plans for its product candidates. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation, risks with respect to: the ability of Slate to retain, attract and hire key personnel; the potential failure to identify additional product candidates and develop or commercialize marketable products; the early stage of Slate’s development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; Slate’s product candidates may cause serious adverse side effects; inability to maintain existing or future collaborations, or the failure of these collaborations; Slate’s reliance on third parties, including for the manufacture of materials for research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of general economic conditions on its business and operations, including Slate’s preclinical studies and clinical trials; the possibility of system failures or security breaches; and risks relating to intellectual property. These forward-looking statements speak only as of the date hereof, and Slate disclaims any obligation to update these statements except as may be required by law. Media and Investor Contacts ICR Healthcare slate@icrhealthcare.com

Executive ChangePhase 3

08 Sep 2026

·firstwordpharma.com

NeuShen raises $80M to advance trio of CNS assets

NeuShen Therapeutics has raised more than $80 million in a series B that will help it advance its pipeline of small molecules for central nervous system (CNS) disorders, including a selective M4 receptor modulator that could eventually compete with Bristol Myers Squibb's Cobenfy (xanomeline/trospium) in schizophrenia.The oversubscribed round was backed by B Capital, Legend Capital, Matrix Partners China, TruMed Investment and SSCI, with existing investor Lilly Asia Ventures increasing its stake. NeuShen closed a series pre-A round of about $20 million in 2022.According to one representative of participating institutional investors in the latest round, NeuShen "has built a unique competitive moat in the CNS space through its strong scientific foundation, differentiated R&D approaches, and forward-looking global strategies."The Shanghai- and Boston-based biotech's assets include NS-136 (laviclidine), a highly selective M4 positive allosteric modulator in Phase II for acute schizophrenia in China. The programme is also moving into Alzheimer's disease agitation, with Phase II studies cleared to start in China and the US; enrollment is expected to begin shortly.The muscarinic approach to schizophrenia was ushered in by the 2024 approval of Cobenfy, which was the first, and so far remains the only, drug in its class cleared for schizophrenia. Unlike Cobenfy's broader muscarinic activity — it acts primarily through M1 and M4 muscarinic receptors — NS-136 is designed to selectively modulate M4.NeuShen has two other clinical-stage programmes. NS-079, a non-hallucinogenic 5-HT2A receptor partial agonist, is being tested in a first-in-human study in Australia for treatment-resistant depression. The company said its compound operates via neuroplasticity modulation to produce "rapid and durable antidepressant effects while significantly reducing safety risks associated with traditional hallucinogenic compounds."Meanwhile, NS-041 (zolankalner), a selective KCNQ2/3 channel opener, is in a Phase II trial for focal-onset seizures, while a Phase II study in major depressive disorder is being prepared.

Phase 2

100 Deals associated with Xanomeline Tartrate/Trospium Chloride

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Schizophrenia	United States	Bristol Myers Squibb Co.	26 Sep 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Autistic Disorder	Phase 3	United States	Bristol Myers Squibb Co.	11 Sep 2026
Autistic Disorder	Phase 3	Australia	Bristol Myers Squibb Co.	11 Sep 2026
Autistic Disorder	Phase 3	Canada	Bristol Myers Squibb Co.	11 Sep 2026
Irritable Mood	Phase 3	United States	Bristol Myers Squibb Co.	11 Sep 2026
Irritable Mood	Phase 3	Australia	Bristol Myers Squibb Co.	11 Sep 2026
Irritable Mood	Phase 3	Canada	Bristol Myers Squibb Co.	11 Sep 2026
Bipolar and Related Disorders	Phase 3	United States	Bristol Myers Squibb Co.	02 Jul 2026
Bipolar and Related Disorders	Phase 3	United States	AndersonBrecon, Inc.	02 Jul 2026
Bipolar and Related Disorders	Phase 3	China	Bristol Myers Squibb Co.	02 Jul 2026
Bipolar and Related Disorders	Phase 3	China	AndersonBrecon, Inc.	02 Jul 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06572449 (CTgov)	Phase 3	Schizophrenia	173	KarXTdose+KarXT (Cohort 1)	ktapsrmifl = yozvjsgayx haskmlvbwv (rknsbuiehq, dteypqwopz - isqninqycg) View more	-	22 Jun 2026
				KarXT (Cohort 2)	ktapsrmifl = ygcwkjzqss haskmlvbwv (rknsbuiehq, ptbfizpzyt - uhdmoaxptr) View more
NCT05145413 (ARISE \| KAR-012, CTgov)	Phase 3	Schizophrenia	396	Placebo	wowsgxksow(phxpkczpft) = nfwdwenqzz mflknpnxyg (ziwgtnytkr, 0.98) View more	-	05 May 2026
NCT05919823 (UNITE-001 \| ZL-2701-001, CTgov)	Phase 3	Schizophrenia	202	trospium+KarXT+xanomeline (Double-Blind Part: KarXT)	gdiwchjhhi(ksxhfqjdev) = ffkmixdgjg mvpebvkmfm (ymtxzhkmeq, 2.122) View more	-	21 Nov 2025
				placebo+KarXT (Double-Blind Part: Placebo)	gdiwchjhhi(ksxhfqjdev) = rgdgjhhpgo mvpebvkmfm (ymtxzhkmeq, 2.074) View more
NCT03697252 (EMERGENT-4, Pubmed \| Ann Pharmacother)	Phase 3	Schizophrenia	-	Xanomeline-Trospium	ueayajbkel(qvquvwounk) = dkvgydcasu gaohcvdrfz (gozfagfqrr )	Positive	01 Oct 2025
NCT04820309 (EMERGENT-5, CTgov)	Phase 3	Schizophrenia	566	Xanomeline and Trospium Chloride Capsules	dkobtpuhsj = tjnxfmnlyk amyiqnlzez (rkqkpkfneu, rnrgmviblf - siqmguwtpo) View more	-	17 Sep 2025
NCT05145413 (ARISE \| KAR-012, Company_Website) Manual	Phase 3	Schizophrenia	-	Cobenfy + APD (mITT)	fncrkslras(gfvtingktm) = lolxsoogef qpuwtiaucn (bywbhusokq, 1.01) Not Met View more	Negative	22 Apr 2025
				Placebo + APD (mITT)	fncrkslras(gfvtingktm) = ahtphltxal qpuwtiaucn (bywbhusokq, 0.98) Not Met View more
NCT04738123 \| NCT04659161 \| NCT03697252 (EMERGENT-2, Pubmed \| J Clin Psychiatry)	Not Applicable	Schizophrenia	683	Xanomeline/Trospium	blqmsyyxhq(hssxzxibke) = midhtdicrx mxgnjhcbik (zbgjauxztw ) View more	Positive	26 Feb 2025
				Placebo	blqmsyyxhq(hssxzxibke) = fxkrfqtpwl mxgnjhcbik (zbgjauxztw ) View more
NCT04738123 (EMERGENT-3 \| EMERGENT-1, EMERGENT-2, EMERGENT-3, CTgov)	Phase 3	Schizophrenia	256	Xanomeline and Trospium Chloride Capsules (KarXT)	dozctrxgkh(azashwcjza) = bvpdhwbhyi vexlwaithi (bbdstlcttg, 1.584) View more	-	09 Dec 2024
				Placebo (Placebo)	dozctrxgkh(azashwcjza) = suhormpyve vexlwaithi (bbdstlcttg, 1.552) View more
NCT04820309 (EMERGENT-5, Company_Website) Manual	Phase 3	Schizophrenia	566	COBENFY	ibcekocmbi(gkzenmpwce) = sxbidvthsd akywkinlzs (syzmxegudd ) View more	Positive	31 Oct 2024
NCT04659174 (EMERGENT-4, Company_Website) Manual	Phase 3	Schizophrenia	156	COBENFY	unkbthbncz(uiatakzdrk) = rlcxvvbbmc stcciuaizy (zyxbvvkrsr )	Positive	31 Oct 2024
				Placebo	-

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis